Replies to post #328 on Affymax, Inc. (AFFY)

[bob smith]

Ty for the post.


Should be a great year, an was a no brainer at $5, or $20


Gl

[surf1944]

07:21 EDT AFFY Affymax to host conference call
Subscribe for More Information
07:04 EDT AFFY Affymax downgraded at Stifel Nicolaus
Subscribe for More Information
06:57 EDT AFFY Affymax downgraded to Hold from Buy at Stifel Nicolaus
Subscribe for More Information
06:16 EDT AFFY Amgen likely to trade up after Affymax recall, says Piper Jaffray
Subscribe for More Information
06:13 EDT AFFY Affymax downgraded to Underperform from Outperform at JMP Securities
JMP Securities downgraded Affymax following the recall of Omontys. Note this is the third downgrade of the day.
06:12 EDT AFFY Affymax downgraded to Neutral from Outperform at RW Baird
RW Baird downgraded Affymax following the recall of Omontys and lowered its price target for shares to $4 from $30. Note Affymax shares were also downgraded this morning at Piper Jaffray.
06:10 EDT AFFY Affymax downgraded to Neutral from Overweight at Piper Jaffray
Subscribe for More Information
February 24, 2013
15:04 EDT AFFY Affymax and Takeda recall Omontys in U.S after serious reactions

1:24AM Affymax and Takeda Pharmaceutical (TKPYY) decide to voluntarily recall all lots of OMONTYS Injection (AFFY) 16.52 : Affymax (AFFY) and Takeda Pharmaceutical (TKPYY) decided to voluntarily recall all lots of OMONTYS Injection to the user level as a result of new postmarketing reports regarding serious hypersensitivity reactions, including anaphylaxis, which can be life-threatening or fatal. The companies have been working actively with the FDA which has indicated its agreement with this decision. The companies have also issued a letter to health care professionals indicating that no new or existing patients should receive OMONTYS. To date, fatal reactions have been reported in approximately 0.02% of patients following the first dose of intravenous administration. The reported serious hypersensitivity reactions have occurred within 30 minutes after such administration of OMONTYS. There have been no reports of such reactions following subsequent dosing, or in patients who have completed their dialysis session.